Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 13, 2026, NDA 50522 (Ceclor), held by Lilly, was first approved by FDA on Apr 4, 1979, with 19 approved supplements and 0 published complete response letters.
First approved: Apr 4, 1979
Review: Standard
Supplements approved: 19
Complete response letters: 0
Approvals and New Uses
The original application and every efficacy supplement, newest first; all 20 submissions below
Date
Submission
Status
Documents
Apr 4, 1979
Original applicationNew active ingredient · Standard review
Approved
None posted
Products
2 strengths and forms
Product
Active ingredient
Marketing
CeclorEQ 125MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · for suspension;oral
CeclorEQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · for suspension;oral
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
